Brain tissue processing, immunohistochemistry and immunofluorescence experiments were performed as described previously37 (link),41 (link). Hemibrains were isolated and post-fixed in 4% (w/v) PFA overnight at 4 °C before preservation in 30% (w/v) sucrose in PBS. Hemibrains were sectioned coronally or sagittally at a thickness of 50 μm on a freezing–sliding microtome, and sections were stored in cryoprotective medium at −20 °C. Free-floating sections were blocked with appropriate serum before incubation at 4 °C with primary antibodies at the following concentrations for confocal microscopy: goat monoclonal anti-CD31 (1:100, AF3628, R&D), fluorescein-labelled lectin (1:200, Vector Laboratories), rabbit monoclonal anti-AQP4 (1:500, AB2218, Millipore Sigma), rat anti-CD13 (1:100, MCA2183EL, Bio-Rad), goat anti-ALPL (1:100, AF2909, R&D), mouse anti-NeuN (1:400, MAB377, Millipore), goat anti-albumin (1:100, NB600-41532, Novus), rabbit anti-transferrin (1:100, ab82411, Abcam or 1:100, AF3987, R&D), rabbit anti-collagen I (1:100, ab21286, Abcam), goat anti-Ibal (1:500, ab5076, Abcam), rabbit anti-MFSD2A (1:300, gift from C. Gu), rat anti-TFRC (1:100, Novus, NB100-64979) and rabbit anti-phospho-STAT3 (1:100, 9145S, CST). Sections were washed, stained with Alexa Fluor-conjugated secondary antibodies (1:250), mounted and coverslipped with ProLong Gold (Life Technologies) before imaging on a confocal laser scanning microscope (Zeiss LSM880). Age-related autofluorescence was quenched with 1 mM CuSO4 in 50 mM ammonium acetate buffer (pH 5), as previously described42 (link). National Institutes of Health ImageJ software was used to quantify the percentage of vasculature (CD31 or AQP4) covered by mIgG, MFSD2A, TFRC, CD13, AQP4 or ALPL, as described previously18 (link). All analyses were performed by a blinded observer. Alizarin red staining was performed as described previously21 (link), with minor adaptations: sections were incubated for 1 h in 40 mM Alizarin red in PBS (pH 7.4) at room temperature, and extensively washed overnight with PBS before mounting. Images of brain sections were acquired by conventional light microscopy to detect calcified nodules. Sections with biotinylated plasma were blocked overnight in 6% BSA at room temperature, detected with streptavidin-Alexa Fluor 647 (1:1,500, Thermo Fisher) for 2 h and washed overnight before mounting. Sections containing L-azidohomoalanine-labelled plasma were blocked overnight in 6% BSA at room temperature, incubated in 45 mM iodoacetamide (Millipore Sigma) in 100% methanol for 1 h, washed, detected with 1.2 μM sDIBO (Thermo Fisher Scientific) in 100% methanol, and washed overnight before mounting. Vascular ALPL activity was measured using the Red Alkaline Phosphatase Substrate Kit (SK-5100, Vector Laboratories) with 20-min incubation. Risedronate-647 (RIS-647, BioVinc, BV500101) was either injected intravenously (retro-orbital) at 8 nmol per mouse and brains were collected 18 h later, or brain sections were stained with 0.1 nM RIS-647 for 2 h at room temperature alongside fluorescein-labelled lectin (1:200, Vector Laboratories).
>
Chemicals & Drugs
>
Organic Chemical
>
Risedronate
Risedronate
Risedronate is a bisphosphonate medication used to treat and prevent osteoporosis, Paget's disease of bone, and other conditions characterized by excessive bone resorption.
It works by inhibiting osteoclast activity, leading to increased bone mineral density and reduced fracture risk.
PubCompare.ai's AI-driven platform can help optimize your Risedronate research by locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Leverage thier powerful comparisons to identify the most effective Risedronate products and procedures, and simplify your research with PubCompare.ai - your one-stop-shop for Risedronate optimizatin.
It works by inhibiting osteoclast activity, leading to increased bone mineral density and reduced fracture risk.
PubCompare.ai's AI-driven platform can help optimize your Risedronate research by locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Leverage thier powerful comparisons to identify the most effective Risedronate products and procedures, and simplify your research with PubCompare.ai - your one-stop-shop for Risedronate optimizatin.
Most cited protocols related to «Risedronate»
Acclimatization
Albumins
Alexa Fluor 647
Alkaline Phosphatase
ALPL protein, human
ammonium acetate
Antibodies
azidohomoalanine
Biologic Preservation
Blood Vessel
Brain
Buffers
Cloning Vectors
Collagen Type I
CXCL9 protein, human
Fluorescein
Fluorescent Antibody Technique
Goat
Gold
Immunohistochemistry
Iodoacetamide
Lectin
Light Microscopy
Methanol
Mice, House
Microscopy, Confocal
Microtomy
Novus
Plasma
Rabbits
Risedronate
Serum
STAT3 Protein
Streptavidin
Sucrose
TFRC protein, human
Tissues
Transferrin
Patients were included in this study if they were female; aged 50 years or older on their index date; had at least one pharmacy or medical claim for a Food and Drug Administration—approved osteoporosis therapy any time between January 1, 2012, and December 31, 2012; had at least 14 months of continuous enrollment with medical and pharmacy benefits before the index date (pre-index period); and had at least 24 months of continuous enrollment with medical and pharmacy benefits after the index date (post-index period).
Patients were excluded from this study if they had a diagnosis or evidence of the following during the pre-index period: treatment with the index therapy, Paget disease of the bone or other osteitis deformans and osteopathies, osteogenesis imperfecta, hypercalcemia, malignant cancer, human immunodeficiency virus infection, or preventive treatment for risk of breast cancer. Patients were also excluded if they had a cancer or metastasis diagnosis before a medical claim for denosumab or zoledronic acid in the post-index period (for patients receiving denosumab and zoledronic acid only), as these therapies may have been used in cancer rather than osteoporosis in these patients.
Treatment groups included injectable and oral therapies, as well as a range of dosing frequencies. The injectable therapies were denosumab subcutaneous (SC) injection every 6 months (Q6M), ibandronate intravenous (IV) injection every 3 months (Q3M), teriparatide daily SC, and zoledronic acid annual IV. The oral therapies were alendronate daily, alendronate weekly, ibandronate monthly, raloxifene daily, risedronate daily, risedronate weekly, and risedronate monthly.
Patients were excluded from this study if they had a diagnosis or evidence of the following during the pre-index period: treatment with the index therapy, Paget disease of the bone or other osteitis deformans and osteopathies, osteogenesis imperfecta, hypercalcemia, malignant cancer, human immunodeficiency virus infection, or preventive treatment for risk of breast cancer. Patients were also excluded if they had a cancer or metastasis diagnosis before a medical claim for denosumab or zoledronic acid in the post-index period (for patients receiving denosumab and zoledronic acid only), as these therapies may have been used in cancer rather than osteoporosis in these patients.
Treatment groups included injectable and oral therapies, as well as a range of dosing frequencies. The injectable therapies were denosumab subcutaneous (SC) injection every 6 months (Q6M), ibandronate intravenous (IV) injection every 3 months (Q3M), teriparatide daily SC, and zoledronic acid annual IV. The oral therapies were alendronate daily, alendronate weekly, ibandronate monthly, raloxifene daily, risedronate daily, risedronate weekly, and risedronate monthly.
Alendronate
Denosumab
Diagnosis
HIV Infections
Hypercalcemia
Ibandronate
Malignant Neoplasm of Breast
Malignant Neoplasms
Neoplasm Metastasis
Osteitis Deformans
Osteogenesis Imperfecta
Osteoporosis
Patients
Periodic Acid
Raloxifene
Risedronate
Subcutaneous Injections
Teriparatide
Woman
Zoledronic Acid
Recruitment of subjects will focus on the Omaha, NE and Lincoln, NE areas as well as Council Bluffs, IA. Women of all races and ethnicities are encouraged to participate in the study. Subjects will be recruited through physician and/or practitioner referral; community presentations (especially when held in conjunction with ongoing corporate and community wellness programs); personal contact; television, radio, and newspaper ads; distributing flyers, postcard and letter mailings; and generation of a website and Facebook page. Recruitment strategies will target the specific women who meet the criteria for our study (e.g., within 5 years’ post-menopause, diagnosis of low bone mass). All recruitment materials will have prior approval from the IRB. Inclusion and exclusion criteria for subject eligibility are summarized in Table 1 .
Inclusion and Exclusion criteria for subjects in study
| Inclusion Criteria | Exclusion Criteria |
|---|---|
| • Women in first 5 years of menopause | • BMO T Score < -2.5 at hip or spine (osteoporosis) |
| • BMD T score between -1.0 and -2.49 at total hip or L1L4 spine (osteoporosis) | • Increased hip and major fracture based on FRAX score |
| • 19 years of age or older | • Bisphosphonates in last 6 months |
| • Health care provider’s permission to be in study | • Currently on estrogen, tamoxifen, Aromatase Inhibitors, others |
| • Weight > 300 pounds | |
| • Serum Vitamin D <10 ng/ml or >100 ng/ml | |
| • Any conditions that prohibit optimal CaD, risedronate, or exercise |
ARID1A protein, human
Aromatase Inhibitors
Bone Density
Diagnosis
Diphosphonates
Eligibility Determination
Ergocalciferol
Estrogens
Ethnicity
Fracture, Bone
Health Personnel
Menopause
Osteoporosis
Physicians
Postmenopause
Risedronate
Serum
Tamoxifen
Vertebral Column
Wellness Programs
Woman
The analysis was carried out from a societal perspective; hence, we included the medical costs, the transportation costs incurred as a consequence of visiting health care institutions for outpatient and inpatient care, and the caregivers' costs during hospitalization. Since the study subjects were women who were aged 55 years or older and most were out of the labor market, productivity loss costs as a consequence of illness were not considered. NHI claims data or statistical reports were utilized to calculate the medical costs for services covered by the NHI. For the services that were not covered by the NHI, the medical costs were estimated based on the overall or disease-specific cost ratios of covered to non-covered services published by NHI corporation. The transportation and caregivers' costs were estimated based on the average numbers of outpatient visits and hospital admissions, and on the numbers of days spent in hospital per year in association with each health state, which were determined from the NHI claims data or statistical reports. All of the costs are based on the 2014 value of U.S. dollars, when $1 was approximately equal to 1,100 Korean won. Both the costs and the effects were discounted at an annual rate of 5%.
For the "healthy", "post-hip fracture" (for the third year and subsequent years after its occurrence), and "post-vertebral fracture" (for the third year and subsequent years after its occurrence) health states, we assigned an annual treatment cost for osteopenia, which included medication costs for prescription drugs (i.e., raloxifene or risedronate), and/or calcium/vitamin D supplements, and costs for routine tests to monitor the BMD status and to manage any adverse effects associated with the medication. We assumed that all patients in the treatment and the control arms underwent radiography, central bone densitometry, and tests for vitamin D levels and the bone markers every 3 years, based on practice guidelines [30 ] and consultations with local clinicians. Those in the treatment arm who received raloxifene or risedronate therapy were assumed to have undergone annual laboratory tests to assess liver function, renal function, and serum calcium, phosphate, and fasting glucose levels to monitor any adverse effects of the drugs.
The average annual costs applied for treating a fracture were estimated from the literature,[3 ] and they differed according to the type of fracture, as follows: $11,909 for non-fatal hip fractures, $5,365 for vertebral fractures, and $2,839 for other fractures. Since the vertebral and hip fracture-related costs persisted for over 1 year,[13 (link)31 (link)] we applied annual post-fracture costs to the second year after these fractures, which were $960 for a hip fracture and $905 for a vertebral fracture.[3 ] For the BC health state, an average annual cost for outpatient and inpatient services provided to patients who were diagnosed with BC was estimated using the NHI claims data from 2011 to 2013, which was $4,933. For the VTE health state, the same data and method were used as those used for the BC health state to calculate the average annual cost of treating VTE, which was $1,711.
Mortality costs were defined as those costs that were incurred during the last stages of life, and they were estimated separately depending on the cause of death, namely, hip fracture, BC, VTE, and other causes. The cost of $17,963 for a BC death was derived from a report entitled "Cost estimation from diagnosis to death of cancer patients", in which the estimated medical costs incurred during the last 12 months before death were determined for each type of cancer based on the National Cancer Surveillance data gathered from 2001 to 2005.[32 ] Since no data nor literature were available that described the mortality costs associated with deaths caused by hip fractures or VTE, we assumed that the mortality costs for these 2 conditions were equal to the average costs per hospital admission for each condition (i.e., $8,878 for a fatal hip fracture and $6,111 for a VTE death), which were estimated based on a recent NHI statistical report. For the other causes of death, the mortality costs were derived from a publication that estimated the health care costs incurred during the last 12 months before deaths from all causes in elderly Korean people in 2001.[33 ]
For the "healthy", "post-hip fracture" (for the third year and subsequent years after its occurrence), and "post-vertebral fracture" (for the third year and subsequent years after its occurrence) health states, we assigned an annual treatment cost for osteopenia, which included medication costs for prescription drugs (i.e., raloxifene or risedronate), and/or calcium/vitamin D supplements, and costs for routine tests to monitor the BMD status and to manage any adverse effects associated with the medication. We assumed that all patients in the treatment and the control arms underwent radiography, central bone densitometry, and tests for vitamin D levels and the bone markers every 3 years, based on practice guidelines [30 ] and consultations with local clinicians. Those in the treatment arm who received raloxifene or risedronate therapy were assumed to have undergone annual laboratory tests to assess liver function, renal function, and serum calcium, phosphate, and fasting glucose levels to monitor any adverse effects of the drugs.
The average annual costs applied for treating a fracture were estimated from the literature,[3 ] and they differed according to the type of fracture, as follows: $11,909 for non-fatal hip fractures, $5,365 for vertebral fractures, and $2,839 for other fractures. Since the vertebral and hip fracture-related costs persisted for over 1 year,[13 (link)31 (link)] we applied annual post-fracture costs to the second year after these fractures, which were $960 for a hip fracture and $905 for a vertebral fracture.[3 ] For the BC health state, an average annual cost for outpatient and inpatient services provided to patients who were diagnosed with BC was estimated using the NHI claims data from 2011 to 2013, which was $4,933. For the VTE health state, the same data and method were used as those used for the BC health state to calculate the average annual cost of treating VTE, which was $1,711.
Mortality costs were defined as those costs that were incurred during the last stages of life, and they were estimated separately depending on the cause of death, namely, hip fracture, BC, VTE, and other causes. The cost of $17,963 for a BC death was derived from a report entitled "Cost estimation from diagnosis to death of cancer patients", in which the estimated medical costs incurred during the last 12 months before death were determined for each type of cancer based on the National Cancer Surveillance data gathered from 2001 to 2005.[32 ] Since no data nor literature were available that described the mortality costs associated with deaths caused by hip fractures or VTE, we assumed that the mortality costs for these 2 conditions were equal to the average costs per hospital admission for each condition (i.e., $8,878 for a fatal hip fracture and $6,111 for a VTE death), which were estimated based on a recent NHI statistical report. For the other causes of death, the mortality costs were derived from a publication that estimated the health care costs incurred during the last 12 months before deaths from all causes in elderly Korean people in 2001.[33 ]
Aged
Bones
Calcium, Dietary
Densitometry
Dietary Supplements
Drug Reaction, Adverse
Ergocalciferol
Fracture, Bone
Glucose
Hip Fractures
Hospitalization
Inpatient
Kidney
Koreans
Liver
Malignant Neoplasms
Obstetric Labor
Osteopenia
Outpatients
Patients
Pharmaceutical Preparations
Phosphates
Prescription Drugs
Raloxifene
Risedronate
Serum
Spinal Fractures
Therapeutics
Vertebra
Woman
X-Rays, Diagnostic
Alendronate
Ethics Committees, Research
Health Planning
Ibandronate
Obstetric Delivery
Risedronate
Therapeutics
Woman
Most recents protocols related to «Risedronate»
All experimental procedures were performed in accordance with the guidelines of the Shanghai Science and Technology Council for Animal Care.
Sixteen weeks old female Sprague-Dawley rats (SLAC Laboratory Animal, Shanghai, China) were acclimated to the environment for 1 week and then randomly assigned into six groups (n = 6 per group): sham operation (SHAM), ovariectomized (OVX), risedronate (RISE), G36G + risedronate (36GRI), G36G, and G48A groups.
Rats were intraperitoneally injected with pentobarbital sodium (40 mg/kg body weight (BW); Sigma, Oakville, Ontario, Canada) for anesthetization and then subjected to bilateral ovariectomy (OVX). The SHAM group received the same procedure except for the OVX [12 (link)]. The ovariectomized rats were used as models of osteoporosis. Fifteen weeks post ovariectomy, the ovariectomized rats in the OVX, RISE, 36GRI, G36G, and G48A groups were subcutaneously injected with PBS (0.1 mL), risedronate (5 μg/kg BW), G36G (10 nmol/kg BW) combined with risedronate (5 μg/kg BW), G36G (10 nmol/kg BW), and G48A (10 nmol/kg BW), respectively, every day for 12 weeks. G36G and G48A were provided by Prof. Dexin Wang from the Institute of Materia Medica, Chinese Academy of Medical Sciences. Rats in the SHAM group underwent bilateral laparotomy and were subcutaneously injected with PBS (0.1 mL) daily for 12 weeks. All rats were double-labeled with tetracycline before euthanasia. The bilateral tibias were isolated and fixed with 70% ethanol. The lumbar vertebrae and femurs were separated, wrapped in saline gauze, and frozen at −20°C.
Sixteen weeks old female Sprague-Dawley rats (SLAC Laboratory Animal, Shanghai, China) were acclimated to the environment for 1 week and then randomly assigned into six groups (n = 6 per group): sham operation (SHAM), ovariectomized (OVX), risedronate (RISE), G36G + risedronate (36GRI), G36G, and G48A groups.
Rats were intraperitoneally injected with pentobarbital sodium (40 mg/kg body weight (BW); Sigma, Oakville, Ontario, Canada) for anesthetization and then subjected to bilateral ovariectomy (OVX). The SHAM group received the same procedure except for the OVX [12 (link)]. The ovariectomized rats were used as models of osteoporosis. Fifteen weeks post ovariectomy, the ovariectomized rats in the OVX, RISE, 36GRI, G36G, and G48A groups were subcutaneously injected with PBS (0.1 mL), risedronate (5 μg/kg BW), G36G (10 nmol/kg BW) combined with risedronate (5 μg/kg BW), G36G (10 nmol/kg BW), and G48A (10 nmol/kg BW), respectively, every day for 12 weeks. G36G and G48A were provided by Prof. Dexin Wang from the Institute of Materia Medica, Chinese Academy of Medical Sciences. Rats in the SHAM group underwent bilateral laparotomy and were subcutaneously injected with PBS (0.1 mL) daily for 12 weeks. All rats were double-labeled with tetracycline before euthanasia. The bilateral tibias were isolated and fixed with 70% ethanol. The lumbar vertebrae and femurs were separated, wrapped in saline gauze, and frozen at −20°C.
Animals
Animals, Laboratory
Body Weight
Chinese
Ethanol
Euthanasia
Female Castrations
Femur
Freezing
Laparotomy
Materia Medica
Osteoporosis
Ovariectomy
Pentobarbital Sodium
Rats, Sprague-Dawley
Rattus norvegicus
Risedronate
Saline Solution
Tetracycline
Tibia
Vertebrae, Lumbar
Woman
Osteoclastic culture medium was supplemented with alendronate or risedronate (10−5 M) from 0 to 72 h, and a control group was treated with osteoclastic medium without BP stimulation in the presence of 2 brefeldins (BFAs) for four hours. Then, the levels of cathepsin K were evaluated by flow cytometry according to a previous report with modifications [30 (link)]. The cellular analysis was performed on a BD FACSCalibur platform (Becton Dickinson, San José, CA), with a total of 5,000 events collected with CellQuest software (Becton Dickinson). Cells were harvested from the culture plate using 0.25% trypsin (Gibco) and centrifuged at 1,500 rpm for 5 minutes. The pelleted cells were washed twice with 1 ml of 1x PBS containing 0.8% bovine serum albumin (BSA) and 0.02% sodium azide. Fixation and permeabilization were performed with an intracellular staining kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's specifications. Osteoclastic cells were washed in 1 ml of 1x PBS plus BSA. A primary rabbit antihuman cathepsin k polyclonal antibody was incubated with the cells for 30–45 minutes at room temperature; we added a secondary rabbit anti-IgG antibody coupled to phycoerythrin isothiocyanate (PE) for 30–45 minutes at room temperature. A control sample was generated following the same steps for intracellular staining (Figure 4 ).
Alendronate
anti-IgG
Cathepsin K
Cells
Flow Cytometry
Immunoglobulins
isothiocyanate
Osteoclasts
Phycoerythrin
Protoplasm
Rabbits
Risedronate
Serum Albumin, Bovine
Sodium Azide
Trypsin
Osteoclast cultures were stimulated with alendronate or risedronate at 10−5 M for 0 to 72 h, and a control group without BP stimulation was included. The levels of Annexin V-fluorescein isothiocyanate (FITC) staining were assessed by flow cytometry. Cell analysis was performed on the BD FACSCalibur™ platform (Becton Dickinson, San José, CA), with a total of 5,000 events collected using CellQuest software (Becton Dickinson). Cells were harvested from the culture plate using 0.25% trypsin (Gibco) and centrifuged at 1,500 rpm for 5 minutes. The pelleted cells were washed twice with 1 ml of 1x PBS containing 0.8% BSA and 0.02% sodium azide. Cell staining was performed with an Annexin V-FITC I apoptosis detection kit from BD Pharmingen™ following the manufacturer's specifications. Osteoclastic cells were washed in 1 ml of 1x PBS containing BSA. Two microlitres of Annexin V + FITC and 2 μL of propidium iodide (PI) were added and incubated for 15–30 minutes in the dark at room temperature (24°C). Finally, 400 μL of 1x binding buffer was added for analysis by flow cytometry (Figure 5 ).
Alendronate
Annexin A1
Annexin A5
Apoptosis
Buffers
Cells
Flow Cytometry
Fluorescein
isothiocyanate
Osteoclasts
Propidium Iodide
Risedronate
Sodium Azide
Trypsin
Osteoblasts and osteoclasts were stimulated separately with three different BPs: alendronate, risedronate, and ibandronate (all at 10−5 M). Both types of cells were stimulated with a conditioned medium from 0 to 96 h. During the course of the experiments, a 500-μL sample of the supernatant was collected from both the control and experimental groups for 0 h to 96 h. The collected supernatant was stored at −70°C in an ultrafreezer (New Air, USA) for subsequent analysis of IL-1β, TNF-α, and sRANKL using enzyme-linked immunosorbent assays (ELISAs; R and D Systems, Minneapolis, MN, USA; PeproTech, USA). The absorbance at 450 nm was measured according to the manufacturer's instructions.
Alendronate
Cells
Culture Media, Conditioned
Enzyme-Linked Immunosorbent Assay
Ibandronate
Interleukin-1 beta
Osteoblasts
Osteoclasts
Risedronate
Tumor Necrosis Factor-alpha
Alendronate (Fosamax; Merck, Rahway, NY, USA), risedronate (Actonel; Proctor and Gamble, Cincinnati, OH, USA), and ibandronate (Boniva; Roche, Indianapolis, IN, USA) were dissolved in phosphate-buffered saline (PBS) at a concentration of 10−5 M.
Actonel
Alendronate
Boniva
Fosamax
Ibandronate
Phosphates
Risedronate
Saline Solution
Top products related to «Risedronate»
Sourced in United States
Risedronate is a laboratory product manufactured by LKT Laboratories. It is a chemical compound used for research purposes. The core function of Risedronate is to serve as a tool for scientific investigation, without any interpretation or extrapolation on its intended use.
The Laser scattering particle size analyzer is a laboratory equipment used to measure the size distribution of particles in a sample. It utilizes the principle of laser light scattering to determine the size and quantity of particles present in the sample.
Sourced in France, United States
Risedronate is a lab equipment product manufactured by Merck Group. It is a bisphosphonate compound used in the analysis and study of various materials and substances. The core function of Risedronate is to serve as a tool for researchers and scientists in their analytical and experimental procedures.
Sourced in Japan, China, Singapore, United States, France
The Shimadzu UV-2600 is a double-beam UV-Vis spectrophotometer designed for accurate and reliable sample analysis. It features a wavelength range of 185 to 900 nm and can measure absorbance, transmittance, and reflectance. The UV-2600 provides high-resolution data and supports a variety of sampling accessories for diverse applications.
Sourced in United States, Poland, Germany, United Kingdom, Belgium, France, Canada, Italy, Hungary, India, Netherlands, Denmark, Mexico, Austria, Spain, Ireland, Sweden
Hydrochloric acid is a clear, colorless, aqueous solution of hydrogen chloride. It is a widely used laboratory reagent that has a core function as an inorganic acid.
Sourced in Japan
Risedronate is a pharmaceutical active ingredient used in the production of laboratory equipment. It is a bisphosphonate compound primarily utilized for its chemical properties and functionality in the development and manufacturing of various lab tools and instruments.
Sourced in United States, Japan
Teriparatide is a laboratory-produced parathyroid hormone used to treat osteoporosis. It functions by stimulating new bone formation.
Sourced in United States, United Kingdom, China, Germany, Canada, Japan, France, Australia, Italy, Switzerland, Spain, Brazil, Belgium, Netherlands, Ireland, Singapore, Poland, Macao, India, Sweden, Denmark, Austria, Argentina, Israel, Lithuania
Trypsin is a proteolytic enzyme that hydrolyzes peptide bonds in proteins. It is commonly used in cell biology and molecular biology applications to facilitate cell detachment and dissociation.
Sourced in United States, Denmark, Austria, United Kingdom
Stata version 13 is a software package designed for data analysis, statistical modeling, and visualization. It provides a comprehensive set of tools for managing, analyzing, and presenting data. Stata 13 offers a wide range of statistical methods, including regression analysis, time-series analysis, and multilevel modeling, among others. The software is suitable for use in various fields, such as economics, social sciences, and medical research.
HA nanopowder is a biocompatible and biodegradable material composed of hydroxyapatite nanoparticles. It has a high surface area-to-volume ratio and can be used in various applications that require a fine, powdered material.
More about "Risedronate"
Risedronate, a bisphosphonate medication, is commonly used to treat and prevent osteoporosis, Paget's disease of bone, and other conditions characterized by excessive bone resorption.
This drug works by inhibiting osteoclast activity, leading to increased bone mineral density and reduced fracture risk.
Researchers can optimize their Risedronate studies by utilizing the powerful capabilities of PubCompare.ai's AI-driven platform.
This tool helps locate the best protocols from literature, preprints, and patents, enhancing the reproducibility and accuracy of Risedronate research.
PubCompare.ai's platform also provides valuable comparisons to identify the most effective Risedronate products and procedures, simplifying the research process.
Leveraging Laser scattering particle size analyzer, UV-2600, and Hydrochloric acid can further enhance the analysis of Risedronate formulations, while incorporating Teriparatide and Trypsin may provide insights into the drug's mechanism of action.
Stata version 13 can be utilized for statistical analysis, and HA nanopowder may be explored as a potential delivery system for Risedronate.
By incorporating these related terms and technologies, researchers can gain a more comprehensive understanding of Risedronate and its applications in the treatment of bone-related conditions.
Thr PubCompare.ai platform serves as a one-stop-shop for Risedronate optimization, simplifying the research process and enhancing the overall quality and effectiveness of Risedronate studies.
This drug works by inhibiting osteoclast activity, leading to increased bone mineral density and reduced fracture risk.
Researchers can optimize their Risedronate studies by utilizing the powerful capabilities of PubCompare.ai's AI-driven platform.
This tool helps locate the best protocols from literature, preprints, and patents, enhancing the reproducibility and accuracy of Risedronate research.
PubCompare.ai's platform also provides valuable comparisons to identify the most effective Risedronate products and procedures, simplifying the research process.
Leveraging Laser scattering particle size analyzer, UV-2600, and Hydrochloric acid can further enhance the analysis of Risedronate formulations, while incorporating Teriparatide and Trypsin may provide insights into the drug's mechanism of action.
Stata version 13 can be utilized for statistical analysis, and HA nanopowder may be explored as a potential delivery system for Risedronate.
By incorporating these related terms and technologies, researchers can gain a more comprehensive understanding of Risedronate and its applications in the treatment of bone-related conditions.
Thr PubCompare.ai platform serves as a one-stop-shop for Risedronate optimization, simplifying the research process and enhancing the overall quality and effectiveness of Risedronate studies.